Status:
COMPLETED
Evaluation of Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.
Lead Sponsor:
Pfizer
Conditions:
Seizure Disorder, Partial
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To determine long-term safety and efficacy of pregabalin in patients with partial seizures.
Eligibility Criteria
Inclusion
- Must have met the inclusion criteria for preceding double-blind study
- Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion
- Cannot be pregnant or considering becoming pregnant during the course of the study.
- Cannot be receiving any concomitant medication that could alter the effectiveness of the pregabalin response or affect seizure frequency.
Key Trial Info
Start Date :
March 1 2002
Trial Type :
INTERVENTIONAL
End Date :
November 1 2005
Estimated Enrollment :
337 Patients enrolled
Trial Details
Trial ID
NCT00150293
Start Date
March 1 2002
End Date
November 1 2005
Last Update
March 5 2015
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Deakin, Australian Capital Territory, Australia, 2600
2
Pfizer Investigational Site
Camperdown, New South Wales, Australia, 2050
3
Pfizer Investigational Site
Chastwood, New South Wales, Australia, 2067
4
Pfizer Investigational Site
Cairns, Queensland, Australia, 4870